PharmGKB: A worldwide resource for pharmacogenomic information

As precision medicine becomes increasingly relevant in healthcare, the field of pharmacogenomics (PGx) also continues to gain prominence in the clinical setting. Leading institutions have begun to implement PGx testing and the amount of published PGx literature increases yearly. The Pharmacogenomics Knowledgebase (PharmGKB; www.pharmgkb.org) is one of the foremost worldwide resources for PGx knowledge, and the organization has been adapting and refocusing its mission along with the current revolution in genomic medicine. The PharmGKB website provides a diverse array of PGx information, from annotations of the primary literature to guidelines for adjusting drug treatment based on genetic information. It is freely available and accessible to everyone from researchers to clinicians to everyday citizens. PharmGKB was found over 17 years ago, but continues to be a vital resource for the entire PGx community and the general public.

[1]  G. Tucker,et al.  Principles of pharmacokinetics. , 1979, Ciba Foundation symposium.

[2]  R. Lewontin,et al.  Somatic versus germinal mutation , 2000 .

[3]  Joshua M. Stuart,et al.  Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.

[4]  Roger L Albin,et al.  Genomic Medicine [4] (multiple letters) , 2003 .

[5]  Alison Abbott,et al.  Special section on human genetics: With your genes? Take one of these, three times a day , 2003, Nature.

[6]  R. Weinshilboum,et al.  Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.

[7]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.

[8]  Russ B. Altman,et al.  Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.

[9]  Gideon Koren,et al.  The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. , 2010, Thyroid : official journal of the American Thyroid Association.

[10]  R. Altman,et al.  Very important pharmacogene summary: thiopurine S-methyltransferase. , 2010, Pharmacogenetics and genomics.

[11]  R. Altman,et al.  Thiopurine pathway. , 2010, Pharmacogenetics and genomics.

[12]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.

[13]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[14]  Michelle Whirl-Carrillo,et al.  From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. , 2011, Biomarkers in medicine.

[15]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[16]  S. Scott,et al.  Personalizing medicine with clinical pharmacogenetics , 2011, Genetics in Medicine.

[17]  J. Gill,et al.  Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. , 2012, Human immunology.

[18]  S. Mallal,et al.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.

[19]  D. Margulies,et al.  Abacavir induces loading of novel self-peptides into HLA-B*57: 01 an autoimmune model for HLA-associated drug hypersensitivity , 2012, AIDS.

[20]  Russ B. Altman,et al.  Chapter 7: Pharmacogenomics , 2012, PLoS Comput. Biol..

[21]  J. McCluskey,et al.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.

[22]  JAMA patient page. Genomic medicine. , 2013, JAMA.

[23]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[24]  E. Gershon,et al.  Ethical and public policy challenges for pharmacogenomics , 2014, Dialogues in clinical neuroscience.

[25]  Teri E. Klein,et al.  Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process , 2014, Current drug metabolism.

[26]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[27]  R. Altman,et al.  PharmGKB summary: abacavir pathway , 2014, Pharmacogenetics and genomics.

[28]  Demetrius J Porche,et al.  Precision Medicine Initiative , 2015, American journal of men's health.

[29]  William E. Evans,et al.  Pharmacogenomics in the clinic , 2015, Nature.

[30]  Teri E Klein,et al.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.

[31]  P. Campbell,et al.  Somatic mutation in cancer and normal cells , 2015, Science.

[32]  L. Dean.  Mercaptopurine Therapy and TPMT Genotype , 2016 .

[33]  Amanda K. Sarata,et al.  The Precision Medicine Initiative , 2016 .

[34]  R. Altman,et al.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems , 2017, Clinical pharmacology and therapeutics.

[35]  Marylyn D. Ritchie,et al.  PharmCAT: A Pharmacogenomics Clinical Annotation Tool , 2017, Clinical pharmacology and therapeutics.

[36]  Marc S. Williams,et al.  Pharmacogenomics , 2019, The Lancet.